复方苦参注射液联合阿帕替尼治疗晚期胃癌的临床分析  

Clinical Analysis of Compound Kushen Injection Combined with Apatinib in The Treatment of Advanced Gastric Cancer

作　　者：李兴坤[1] 李竹生[2] Li Xing-kun;Li Zhu-sheng(Oncology Department of Puyang People's Hospital,Puyang 457000,Henan Province,China;Oncology Department of Puyang Hospital of Traditional Chinese Medicine,Puyang 457000,Henan Province,China)

机构地区：[1]濮阳市人民医院肿瘤科,河南濮阳457000 [2]濮阳市中医院肿瘤科,河南濮阳457000

出　　处：《罕少疾病杂志》2023年第7期71-73,共3页Journal of Rare and Uncommon Diseases

摘　　要：目的探讨复方苦参注射液联合阿帕替尼在晚期胃癌治疗中的应用效果。方法本研究为前瞻性随机对照研究,纳入2020年3月至2022年3月医院收治的晚期胃癌患者为研究对象,采用随机数字表法分为两组。两组患者均给予常规治疗,对照组口服阿帕替尼治疗,观察组应用静脉滴注复方苦参注射液联合阿帕替尼治疗,连续治疗30d。采用χ^(2)检验、秩和检验比较两组患者临床治疗效果、毒副反应发生情况及分级;采用t检验比较两组患者治疗前后肿瘤标志物[糖类抗原125(CA125)、CA19-9、癌胚抗原(CEA)]、T淋巴细胞(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))水平。结果共纳入117例符合标准的晚期胃癌患者,观察组58例,对照组59例;试验过程中对照组脱落1例,脱落原因为发生Ⅳ级毒副反应停药,最终每组纳入58例患者作为研究对象。治疗30d,观察组治疗有效率(41.38%)高于对照组(20.69%)(P<0.05)。治疗30d,两组患者CA125、CA19-9、CEA水平降低,且观察组低于对照组(P<0.05)。治疗30d,观察组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于治疗前,且高于对照组(P<0.05);对照组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)与治疗前比较差异无统计学意义(P>0.05)。观察组患者肝功能损伤、脱发、消化道症状、骨髓抑制的发生率(36.21%、20.69%、43.10%、44.83%)低于对照组(55.17%、37.93%、65.52%、70.69%),毒副反应分级低于对照组(P<0.05)。结论在化疗的基础上,加用复方苦参注射液联合阿帕替尼治疗,不仅能提高常规化疗效果,显著降低患者肿瘤标志物水平,同时能改善患者免疫功能,减轻化疗毒副反应,发挥增效减毒、增强免疫的功效。Objective To explore the effect of compound Kushen injection combined with apatinib in the treatment of advanced gastric cancer.Methods This study is a prospective randomized controlled study that included patients with advanced gastric cancer admitted to hospitals from March 2020 to March 2022 as the study subjects.They were divided into two groups using a random number table method.The patients in both groups were given routine treatment.The control group was treated with apatinib orally,and the observation group was treated with compound Kushen injection combined with apatinib by intravenous drip for 30 consecutive days.χ^(2)test and rank sum test were used to compare the clinical treatment effect,toxic and side effects and grades of the two groups.t-test was used to compare the levels of tumor markers[carbohydrate antigen 125(CA125),CA19-9,carcinoembryonic antigen(CEA)],T lymphocytes(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))between the two groups before and after treatment.Results A total of 117 patients with advanced gastric cancer were included,58 in the observation group and 59 in the control group.During the trial,one patient in the control group fell off because of gradeⅣtoxic side effect and drug withdrawal.Finally,58 patients in each group were included as study subjects.After 30 days of treatment,the effective rate of the observation group(41.38%)was higher than that of the control group(20.69%)(P<0.05).After 30 days of treatment,the levels of CA125,CA19-9,and CEA in both groups of patients decreased,and the observation group was lower than the control group(P<0.05).After 30 days of treatment,the CD3^(+),CD4^(+),CD4^(+)/CD8^(+)levels in the observation group were higher than before treatment and higher than those in the control group(P<0.05).There was no statistical significant difference in CD3^(+),CD4^(+),CD4^(+)/CD8^(+)between the control group and the pre-treatment group(P>0.05).The incidence of liver function injury,alopecia,gastrointestinal symptoms and bone marrow suppression in the observation group

关 键 词：晚期胃癌 阿帕替尼 复方苦参注射液 治疗效果 毒副反应 

分 类 号：R735.2[医药卫生—肿瘤]